CN105085647B - 天然抗感染抗氧化双功能肽Pb-CATH2及其基因与应用 - Google Patents
天然抗感染抗氧化双功能肽Pb-CATH2及其基因与应用 Download PDFInfo
- Publication number
- CN105085647B CN105085647B CN201510560842.7A CN201510560842A CN105085647B CN 105085647 B CN105085647 B CN 105085647B CN 201510560842 A CN201510560842 A CN 201510560842A CN 105085647 B CN105085647 B CN 105085647B
- Authority
- CN
- China
- Prior art keywords
- cath2
- infective
- oxidant
- gene
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 38
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 24
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 21
- 230000002924 anti-infective effect Effects 0.000 title claims abstract description 15
- 239000003963 antioxidant agent Substances 0.000 title claims abstract description 13
- 235000006708 antioxidants Nutrition 0.000 title claims abstract description 13
- 230000001588 bifunctional effect Effects 0.000 title claims description 18
- 108060001132 cathelicidin Proteins 0.000 claims abstract description 21
- 102000014509 cathelicidin Human genes 0.000 claims abstract description 19
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 13
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 11
- 239000002773 nucleotide Substances 0.000 claims abstract description 10
- 230000036541 health Effects 0.000 claims abstract description 7
- 229920001184 polypeptide Polymers 0.000 claims abstract description 7
- 230000003064 anti-oxidating effect Effects 0.000 claims abstract description 5
- 235000013305 food Nutrition 0.000 claims abstract description 5
- 239000002537 cosmetic Substances 0.000 claims abstract description 3
- 125000000539 amino acid group Chemical group 0.000 claims abstract 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 4
- 239000003674 animal food additive Substances 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- AQGDXJQRVOCUQX-UHFFFAOYSA-N N.[S] Chemical compound N.[S] AQGDXJQRVOCUQX-UHFFFAOYSA-N 0.000 claims 1
- 241000760756 Python bivittatus Species 0.000 abstract description 30
- 241000894006 Bacteria Species 0.000 abstract description 27
- 150000001413 amino acids Chemical class 0.000 abstract description 13
- 238000003786 synthesis reaction Methods 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000126 substance Substances 0.000 abstract description 6
- 206010018910 Haemolysis Diseases 0.000 abstract description 5
- 230000008588 hemolysis Effects 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 4
- 241000192125 Firmicutes Species 0.000 abstract description 3
- 241000233866 Fungi Species 0.000 abstract description 3
- 239000000654 additive Substances 0.000 abstract description 3
- 230000000996 additive effect Effects 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 238000010353 genetic engineering Methods 0.000 abstract description 3
- 230000000845 anti-microbial effect Effects 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 239000013615 primer Substances 0.000 description 21
- 239000000243 solution Substances 0.000 description 18
- 239000000523 sample Substances 0.000 description 14
- 230000000844 anti-bacterial effect Effects 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 10
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 230000031700 light absorption Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000007760 free radical scavenging Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229960002260 meropenem Drugs 0.000 description 4
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000002000 scavenging effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229910021642 ultra pure water Inorganic materials 0.000 description 3
- 239000012498 ultrapure water Substances 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241001521293 Python Species 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 108010007004 cathelin Proteins 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000012215 gene cloning Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000005839 radical cations Chemical class 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 101800000068 Antioxidant peptide Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical class CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 229910002567 K2S2O8 Inorganic materials 0.000 description 1
- 206010024774 Localised infection Diseases 0.000 description 1
- 108060003100 Magainin Proteins 0.000 description 1
- ZSEMWHCVIJETNE-UHFFFAOYSA-N N1=CC=CC2=CC(=C3C=CC=NC3=C12)S(=O)(=O)O.C(C)N1CSC2=C1C=CC=C2 Chemical compound N1=CC=CC2=CC(=C3C=CC=NC3=C12)S(=O)(=O)O.C(C)N1CSC2=C1C=CC=C2 ZSEMWHCVIJETNE-UHFFFAOYSA-N 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- -1 Oxygen anion Chemical class 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 108010078256 antimicrobial peptide IB-367 Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000010429 evolutionary process Effects 0.000 description 1
- 238000012683 free radical ring-opening polymerization Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 102000050459 human LTF Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 108010062940 pexiganan Proteins 0.000 description 1
- KGZGFSNZWHMDGZ-KAYYGGFYSA-N pexiganan Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 KGZGFSNZWHMDGZ-KAYYGGFYSA-N 0.000 description 1
- 229950001731 pexiganan Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical class [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 235000019394 potassium persulphate Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012599 radical scavenging assay Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明属于生物医学技术领域,具体是一种缅甸蟒蛇来源的cathelicidin家族具有抗感染抗氧化双功能的多肽Pb‑CATH2及其基因、制备方法和应用。Pb‑CATH2是直链多肽,含有29个氨基酸残基,理论等电点为12.49,理论分子量是3389.08Da。Pb‑CATH2的前体基因由480个核苷酸组成,其中编码成熟肽部分的为第391‑477位核苷酸。Pb‑CATH2富含碱性氨基酸和疏水性氨基酸,分子量小、结构简单,方便化学合成及基因工程制备。Pb‑CATH2不仅具有很强的广谱抗微生物活性,对革兰氏阳性菌、革兰氏阴性菌及真菌均具有很好的活性,还有一定的抗氧化作用以及低溶血活性等有益特点。故可作为抗感染抗氧化药物开发,以及作为化妆品、保健品、食品、饲料等日化中的添加剂被应用,具有很好的应用前景。
Description
技术领域
本发明提供一种来源于缅甸蟒蛇(Python molurus bivittatus)的cathelicidin家族的具有抗感染抗氧化双功能的多肽Pb-CATH2及其编码基因,氨基酸序列和其在化妆品、保健品、食品、饲料等日化添加剂及抗感染医药领域中的应用,属于生物医学技术领域。
背景技术
Cathelicidin是一类由N端信号肽区域、中间保守cathelin结构域和C端高度特异的成熟肽区域构成的具有多功能的宿主抗菌肽家族,结构特点是:具有N端信号肽区域(30个残基左右)、中间保守cathelin结构域(99-114个残基)和C端高度特异的成熟肽区域(12-100个残基)。Cathelicidin具有广谱的抗菌活性,能快速、广谱地杀灭多种病原微生物,包括革兰阳性菌、革兰阴性菌、真菌、寄生虫和病毒等,特别是对许多临床耐药细菌同样具有作用,这引起了人们的注意。除此之外,cathelicidin还具有许多其他生物学活性,如对多种免疫细胞(中性粒细胞、单核细胞、肥大细胞和T细胞)具有趋化作用、诱导肥大细胞脱粒和组织胺释放、调节巨噬细胞转录、促进伤口愈合、诱导血管发生、诱导变异细胞系细胞凋亡和淋巴细胞活化等。这些优势使其在临床的应用有着良好的前景。
关于抗菌肽药物,目前cathelicidin的研究热点主要集中在消炎、抗感染和抗真菌等方面,应用方式可以是局部的也可以是系统的,剂型可以是口服也可以外用。尤其由于阳离子抗菌肽的表达与皮炎、侵入性烧伤脓血症、肿瘤病毒引起的肉赘等之间的病理联系,这些抗菌肽对这些疾病的局部治疗有较好的开发前景。目前有部分抗菌肽药物已进入临床试验阶段,例如Pexiganan是爪蟾抗菌肽Magainin的类似物,目前已作为治疗足部感染药物进入临床试验阶段,它也是第一个进行商业开发的抗菌肽;Hlf1-11是人乳铁蛋白前11个氨基酸残基组成的抗菌肽,通过Ⅰ/Ⅱ期临床试验研究表明Hlf1-1通过静脉给药时是安全的、耐受性良好的;来源于猪protegrin的IB-367用于治疗肿瘤患者口腔溃疡,已进入临床III期试验等。Cathelicidin的应用不仅限于医药领域,在农业、畜牧业和日化用品领域,cathelicidin也存在巨大的应用潜能。
2002年,世界卫生组织(WHO)发表公告指出“在牲畜养殖过程中,停止以往惯用的饲料添加剂抗生素的做法,将在不危害动物和农民利益的前提下,可减少对人类健康的威胁。抗生素作为饲料添加剂应用于动物生产中,对畜牧业的发展起了重要的作用,但是其在动物体内和动物产品中的残留,以及病原菌产生的抗药性问题,对人类的健康和环境产生了负面的影响。并且完全使我国出口肉类,海产品等受到了限制,从而影响收益。寻找新型、安全的抗菌剂代替抗生素,已成为当前国内外饲料学科的一项重要内容。抗菌肽具有广谱的抗菌作用,对畜禽具有促生长和治疗疾病的功能,是无毒、无害、无残留的绿色产品,有望成为抗生素的替代品,在畜牧生产上发挥重要的作用。
机体氧化反应产生的自由基(free radical)是含有一不成对电子的原子团,如超氧阴离子、羟自由基等。自由基具有强氧化性,随着年龄增长或在病理状态下,自由基产生过多若不能被及时清除,就会在细胞内堆积,与机体内的生物大分子,如蛋白质、核酸、脂质等相互作用,生成过多的氧化物和过氧化物,最终影响机体新陈代谢,并对机体产生不可逆的损伤。衰老及很多慢性疾病如癌症、心血管疾病、肺气肿、肝硬化、关节炎等都和自由基的损伤有关。尽管机体存在抗氧化防御系统,但其并不能完全有效地抵御或修复氧化作用带来的损伤。如何适当的清除自由基,使其在体内维持在一个较低的水平,从而延缓机体衰老,是当前一个重要的研究课题。
在漫长的进化过程中生物体形成了多种不同的自由基清除系统以抵抗活性氧自由基对机体的损害,包括非基因编码的小分子物质,如尿酸、维生素C和辅酶Q等;基因编码的大分子抗氧化酶类,如超氧化物歧化酶(SOD)、过氧化氢酶和谷胱甘肽酶系统;基因编码的小分子抗氧化肽类等。其中小分子抗氧化肽热稳定性强、水溶性好、无毒无副作用,可被人体内的酶系降解、消化,减少热处理时间,能够最大条件保持食品的营养价值,可用于食品中的抗氧化剂;在医药中制备抗氧化药物;在护肤品种作为添加剂,具有很好的应用前景。
缅甸蟒蛇(Python molurus bivittatus),是蛇亚目蟒科蟒属印度蟒的亚种之一,以体型巨大著称,平均身长至高可达7米,体重可达91公斤,也是世界上最巨型的六种蛇类之一。缅甸蟒属于东南亚地区的本土品种,是一种夜行性蛇类,多居于热带森林里,在中国多见于广东、广西、福建、云南、海南、贵州等地。目前关于缅甸蟒蛇cathelicidin家族抗感染抗氧化双功能肽的研究和应用还没有报道。
发明内容
本发明提供一种在亚微摩尔剂量下即具有很强的抗微生物抗氧化活性的来源于缅甸蟒蛇的一种双功能肽Pb-CATH2及其基因、氨基酸序列和应用。本发明的目的是基于上述理论研究和现有技术基础,提供一种具有抗感染抗氧化活性的缅甸蟒蛇双功能肽Pb-CATH2及其应用,着重医药制备,化妆品、保健品、食品和新型饲料添加剂等中的应用。
为了实现本发明的目的,本发明提供了如下技术方案:
Pb-CATH2是缅甸蟒蛇cathelicidin基因编码的一种直链多肽,含有29个氨基酸残基,分子量是3389.08Da,理论等电点(pI)为12.49,一种碱性多肽(含有11个碱性氨基酸残基)。
缅甸蟒蛇双功能肽Pb-CATH2基因的克隆包括:
缅甸蟒蛇肺总RNA提取,mRNA纯化,mRNA反转录及cDNA文库构建,设计引物,利用PCR方法筛选缅甸蟒蛇抗菌肽Pb-CATH2基因。5’端引物分别为P1(5'-GATGGAGATCCACCTGGGAGAA-3')和P2(5'-GCTGGACTTCACCTTGAAGGAGAC-3'),PCR另一扩增引物为CLONTECH公司CreatorTM SMART TM cDNA Library Construction Kit中的3’PCRPrimer引物,其序列为5’–ATTCTAGAGGCCGAGGCGGCCGACATG–3’。获得阳性单克隆进行基因核苷酸序列测定。基因测序结果表明编码缅甸蟒蛇抗菌肽Pb-CATH2前体cathelicidin的基因由480个核苷酸组成,自5’端至3’端序列为:
编码缅甸蟒蛇成熟肽Pb-CATH2的为391位到477位的核苷酸序列,其编码的氨基酸序列为:Lys1-Arg2-Asn3-Gly4-Phe5-Arg6-Lys7-Phe8-Met9-Arg10-Arg11-Leu12-Lys13-Lys14-Phe15-Phe16-Ala17-Gly18-Gly19-Gly20-Ser21-Ser22-Ile23-Ala24-His25-ILe26-Lys27-Leu28-His29。
缅甸蟒蛇双功能肽Pb-CATH2基因作为基因工程制备缅甸蟒蛇双功能肽Pb-CATH2的应用。
Pb-CATH2的化学制备方法:
根据编码缅甸蟒蛇cathelicidin双功能肽基因推断的成熟肽Pb-CATH2氨基酸序列,用自动多肽合成仪(433A,Applied Biosystems)合成其全序列。通过HPLC反相柱层析脱盐纯化,并确定其纯度大于95%。用基质辅助激光解析电离飞行时间质谱(MALDI-TOF)测定其分子量,等电聚焦电泳测定等电点,用自动氨基酸测序仪测定氨基酸序列结构。合成的Pb-CATH2肽可以溶于灭菌超纯水,用于药理活性检测。
本发明的有益效果在于:
基因克隆得到编码缅甸蟒蛇cathelicidin抗感染抗氧化双功能肽的基因,通过化学合成方法得到成熟肽Pb-CATH2。该双功能肽富含碱性氨基酸,具有抗氧化活性及强的抗菌活性,抗菌实验显示其对多种临床耐药菌也有较好的杀灭作用。另外,其还具有很低细胞毒性,无溶血活性,结构简单,不含有二硫键及环状结构,方便化学合成及基因工程制备。
附图说明
附图是Pb-CATH2对E.coil ATCC25922的杀菌动力学图。
具体实施方式
下面结合技术方案详细叙述本发明的具体实施例,但本发明的内容并不局限于此。
严格参照试剂盒说明书,采用RNeasy AxyPrepTM Multisource Total RNAMiniprep Kit(Qiagen,union city,CA,USA)提取缅甸蟒肺组织总RNA,然后利用CreatorTMSMART TM cDNA Library Construction Kit建库试剂盒构建缅甸蟒蛇肺组织cDNA文库。利用试剂盒中PowerScript Reverse Transcriptase反转录合成cDNA第一链,引物为:
正向SMART Ⅳ Oligonucleotide引物:
5'–AAGCAGTGGTATCAACGCAGAGTGGCCATTACGGCCGGG–3'
反向CDSⅢ/3'PCR引物:5’–ATTCTAGAGGCCGAGGCGGCCGACATG-d(T)30N-1N–3’(N=A,C,G,or T;N-1=A,G,or C).
利用Advantage DNA Polymerase合成cDNA第二链,引物为:正向5'–AAGCAGTGGTATCAACGCAGAGT-3',反向引物同为CDSⅢ/3'PCR Primer。.
设计两条特异性正向引物(P1、P2)和一条反向非特异性通用引物(3'PCRPrimer),以缅甸蟒蛇肺cDNA为模板,采用半巢式PCR的方法扩增cathelicidin的cDNA。
正向P1:5'-GATGGAGATCCACCTGGGAGAA-3';
正向P2:5'-GCTGGACTTCACCTTGAAGGAGAC-3';
反向非特异性通用引物为3'PCR Primer,其序列为:
5‘-ATTCTAGAGGCCGAGGCGGCCGACATG-3’。
所获阳性单克隆进行基因核苷酸序列测定,pMD19-T Vecter测序通用引物:
正向M13F:5'-CGCCAGGGTTTTCCCAGTCACGAC-3';
反向M13R:5'-GAGCGGATAACAATTTCACACAGG-3';
具体步骤如下:
第一步、缅甸蟒蛇肺总RNA提取(以下实验所用器具和试剂均经过DEPC水处理,无RNase):
A.从一岁龄大小的雄性缅甸蟒蛇各种新鲜组织中取下绿豆大小个小块,分别放于标记好的冻存管中,迅速置于液氮中保存备用;
B.将保存在液氮中的组织材料取出,放入预冷的研钵内,迅速充分研磨,期间不断向研钵内加入少许液氮;将大约30mg的组织粉末转移至预冷的1.5ml离心管中,向其中分别加入400μl Buffer R-I(裂解液,RNA Miniprep Kit提供),用21-25号针头的注射器反复抽吸8-10次,转入1.5ml离心管中,加入150μl Buffer R-Ⅱ,涡旋振荡15-30s,4℃,12000rpm离心5min;
C.取上清转移至新的1.5ml离心管中,加入250ul异丙醇,迅速吸打混匀;将混合液分别转移至2ml离心管中(试剂盒内提供),4℃,6000rpm离心1min;弃废液,将制备管置回到2ml离心管中,然后加入500μl Buffer W1A,4℃,12000rpm离心1min;弃废液,加入700μlBufferW2A,4℃,12000rpm离心1min;弃废液,加入700μl Buffer W2A,4℃,12000rpm离心1min;弃废液,空管12000rpm离心1min;将离心吸附柱转移至新的1.5ml离心管中,然后直接向吸附膜上滴加70-100μl Buffer TE,室温放置1min,4℃,12000rpm离心1min洗脱得到总RNA;
第二步、缅甸蟒蛇肺组织cDNA文库的构建
第一链的合成(mRNA反转录):
A.在新的0.2ml PCR管(无DNase和RNase)中配制下列混合液:
混合均匀,短暂离心;PCR仪中72℃保温2min后,然后冰浴2min;短暂离心后,在上述管中配制如下反转录反应液:
混合均匀后,短暂离心;在PCR仪中完成以下程序:
42℃,90min;68℃,10min;冰浴终止反应。cDNA保存于-80℃。
第二链的合成:
轻弹管壁,短暂离心,放入提前预热的PCR仪中,反应条件为:95℃,1min,21cycles(95℃,15s;65℃,30s;68℃,6min)。取5μl的产物电泳检测分析。
第三步、半巢式PCR进行缅甸蟒蛇cathelicidin的基因克隆筛选
引物使用前先12000rpm离心5min,然后根据标明的摩尔数加入相应体积的ddH2O溶解至20μM的浓度。合成的肺组织cDNA稀释20倍作为模板,以P1和3'PCR Primer为引物,进行第一次PCR扩增。在0.2ml PCR管中加入下列试剂:
混匀后,短暂离心。PCR条件为:94℃变性5min;28个循环:94℃变性30s,56℃退火30s,72℃延伸50s;72℃延伸10min;4℃保存。反应结束后,取5μl产物于1%琼脂糖凝胶电泳检测目的条带。
取上步PCR产物1μl用ddH2O稀释100倍作为模板,以P2和3'PCR Primer为引物,进行第二次PCR扩增。在0.2ml PCR管中先后加入下列试剂:
PCR条件为:94℃变性5min;28个循环:94℃变性30s,56℃退火30s,72℃延伸50s;72℃延伸10min;4℃保存。反应结束后,取5μl,1%琼脂糖凝胶电泳检测目的条带。
扩增完成后用胶回收试剂盒(天根生物)进行目的片段回收。将回收的目的DNA片段与测序载体pMD19-T Vecter连接,转化进CaCl2法制备好的DH5α感受态细胞。取100μl转化菌液均匀涂布在含有100μg/ml氨苄青霉素(Amp)的LB琼脂培养基平板上;表面晾干后,放在37℃恒温培养箱中倒置培养12-16h。挑取单菌落用M13引物PCR检测插入片段大小。挑取阳性菌落,摇菌提取质粒,使用Applied Biosystems DNA sequencer,model ABI PRISM377进行核苷酸测序。
第四步、缅甸蟒蛇cathelicidin的基因序列测定和结果:
编码其前体cathelicidin的基因由480个核苷酸组成,自5’端至3’端序列为:
缅甸蟒蛇cathelicidin编码区的cDNA核苷酸的序列表为:序列长度为480个碱基,序列类型:核酸,链数:单链,拓扑学:直链状,序列种类:cDNA,来源:缅甸蟒蛇肺。
编码缅甸蟒蛇cathelicidin成熟肽Pb-CATH2为391位到477位的核苷酸序列,其编码的氨基酸序列为:Lys1-Arg2-Asn3-Gly4-Phe5-Arg6-Lys7-Phe8-Met9-Arg10-Arg11-Leu12-Lys13-Lys14-Phe15-Phe16-Ala17-Gly18-Gly19-Gly20-Ser21-Ser22-Ile23-Ala24-His25-ILe26-Lys27-Leu28-His29。
Pb-CATH2的化学制备方法:
Ⅰ、根据编码缅甸蟒蛇cathelicidin基因推断的成熟肽Pb-CATH2氨基酸序列,用自动多肽合成仪(Applied Biosystems)合成其全序列,通过HPLC反相柱层析脱盐纯化,并确定其纯度大于95%。
Ⅱ、分子量测定采用基质辅助激光解析电离飞行时间质谱(MALDI-TOF),等电聚焦电泳测定等电点,用自动氨基酸测序仪测定氨基酸序列结构。合成的Pb-CATH2抗菌肽可以溶于灭菌超纯水,用于药理活性检测。
缅甸蟒蛇双功能肽Pb-CATH2的药理实验:
1.Pb-CATH2抗菌活性检测:
将化学合成的Pb-CATH2以2mg/ml的浓度溶解在无菌超纯水中;用接种环挑取新活化的微生物,然后均匀涂布在新的LB琼脂板上;将直径0.5cm的圆形无菌滤纸片放在上述琼脂板上,然后向纸片上滴加10μl Pb-CATH2样品溶液;放入37℃恒温培养箱中培养12-24h;观察抑菌圈形成与否,将对Pb-CATH2敏感的菌株记录下来。
2.Pb-CATH2对敏感菌株最小抑菌浓度(Minimum Inhibitory Concentration,MIC)的测定。
该实验以无菌的LB液体培养基作阴性对照,观察有细菌生长孔的浓度与无细菌生长的孔的浓度,取平均值即为最小抑菌浓度。
挑取新活化的微生物,接种至无菌液体LB培养基,37℃恒温振荡器中200rpm培养10-16h至对数生长期;用紫外分光光度计测菌液600nm处的吸光值,吸光值为1时,浓度大约为109cfu/ml,将菌液用无菌液体LB培养基稀释至2×105cfu/ml,冰上待用;用二倍稀释法在96微孔板上用无菌LB培养基配制浓度梯度为200μg/ml、100μg/ml、50μg/ml、25μg/ml、12.5μg/ml、6.25μg/ml、3.13μg/ml、1.56μg/ml、0.78μg/ml、0.39μg/ml、0.20μg/ml的Pb-CATH2样品溶液,每孔50μl;每孔加入50μl上述稀释菌液;在恒温振荡器中37℃,100rpm振荡培养10-16h;使用酶标仪测OD600nm吸光值或肉眼观察;上述实验重复3次。
表1 Pb-CATH2的最小抑菌浓度(MIC)
*MIC:最小抑菌浓度;ND:抑菌圈实验检测无抑菌活性;IS:临床分离菌株。以上结果为三次独立重复实验平均值。
由表1可见,Pb-CATH2具有广谱的抗菌活性,其MIC值大都在5.53-22.13μM之间,抗菌活性明显强于传统使用的抗生素氨苄青霉素(MIC值大都在12.62–201.9μM之间)。Pb-CATH2不仅对革兰氏阳性菌(G+)和革兰氏阴性菌(G-)具有抗菌活性,还对测试用的所有真菌都有强的抗菌活性,特别是对几种常见的临床分离的致病菌株如肺克杆菌,铜绿假单胞菌,表皮葡萄球菌以及白色念珠菌等具有杀菌作用。此外由表中可以看出Pb-CATH2对痢疾杆菌最为敏感,最小抑菌浓度仅为0.69μM。
3.Pb-CATH2的杀菌动力学检测。
活化菌株:将大肠杆菌ATCC25922划线接种到LB固体培养基平板上,置于37℃培养箱中倒置培养至单菌落长出。用接种环挑取单菌落接种到LB液体培养基中,37℃振荡过夜培养至对数生长期。用新鲜的LB液体培养基将菌液稀释至1×105CFU/ml的浓度,备用。
将Pb-CATH2或者美罗培南加入到稀释好的菌液中,使其终浓度为5倍MIC(阴性对照用相应体积的灭菌双蒸水)。加入样品的菌液迅速放入37℃振荡培养箱中培养,分别于0min、10min、20min、30min、45min、60min、90min及120min时取10μl菌液用灭菌的LB液体培养基稀释100倍,然后取100ul稀释后的菌液涂LB固体培养基,37℃过夜培养,计算菌落数。
由附图可知,Pb-CATH2杀菌迅速,在10分钟内就能够杀死全部大肠杆菌ATCC25922细胞;而阳性对照美罗培南作用相对较慢,需要90分钟才能全部杀死大肠杆菌ATCC25922。美罗培南是人工合成的广谱碳青霉烯类抗生素,通过抑制细菌细胞壁的合成而发挥抗菌作用。与美罗培南相比,Pb-CATH2的快速杀菌能力表明其作用机制不可能是通过抑制细菌细胞壁的合成,也不可能是通过抑制细菌细胞内核酸、蛋白质的合成或抑制细菌某些蛋白酶的活性,因为这需要一定的作用时间才能导致细菌的死亡。可以看出Pb-CATH2具有异于传统抗生素的独特的杀菌机理,不易引起菌体耐药性的产生,暗示Pb-CATH2具有良好的抗菌药用前景。
4.Pb-CATH2的抗氧化活性分析
4.1 DPPH自由基清除活性(DPPH radical scavenging assay)
称取一定量的DPPH(2,2-diphenyl-1-picrylhydrazyl hydrate,Sigma,美国),用甲醇溶解,配成6×10-5M的溶液,现配现用。将48μl DPPH溶液和2μl样品混合(最终样品与DPPH的质量比为3:1),室温下避光静置30min,于517nm处测定吸光值。空白对照组以样品溶解介质代替待测样品。实验做三个平行,紫外分光光度计调零时使用甲醇。
DPPH·清除率(%)=(AB-AA)/AB×100%(AB:空白对照组吸光值;AA:样品组吸光值)。
表2 Pb-CATH2的DPPH自由基清除率I%
样品浓度(μg/ml) | 40 | 80 | 160 | 320 |
DPPH自由基清除率I% | 10.11 | 15.45 | 21.36 | 40.75 |
由表2所示,Pb-CATH2具有一定的DPPH自由基清除活性。随着样品浓度的增加,其DPPH自由基的清除率也在升高,说明Pb-CATH2的抗氧化能力具有一定的浓度依赖性。
4.2 ABTS·+自由基正离子清除活性
ABTS(3-ethylbezothiazoline-6-sulfonic acid)(3-乙基苯并噻唑啉-6-磺酸)用PBS缓冲液(pH7.4)配成2mM的ABTS储存液。将ABTS储存液和70mM过硫酸钾(K2S2O8)水溶液按体积比250:1混合,于室温避光放置15-16h。试验开始前,将ABTS·+释至734nm波长处的吸光值为0.80±0.03。将4μl不同浓度的Pb-CATH2和96μl上述校正过的ABTS·+溶液混合,室温放置10min后,于734nm波长处检测反应液的吸光值。空白对照组为溶解样品所用灭菌去离子水。实验做三个平行。
ABTS·+清除率I(%)=(AB-AA)/AB×100%(AB:空白对照组吸光值;AA:样品组吸光值)。
表3 Pb-CATH2对ABTS·+自由基正离子清除活性I(%)
样品浓度(μg/ml) | 40 | 80 | 160 | 320 |
ABTS·+清除率I(%) | 6.95 | 14.76 | 37.18 | 45.23 |
为了进一步确认Pb-CATH2的抗氧化活性,我们检测了Pb-CATH2对ABTS·+自由基正离子清除活性,结果如表3所示,Pb-CATH2具有抗氧化活性,且在样品浓度为320μg/ml时,ABTS·+自由基清除率最强,达到45.23%。Pb-CATH2的抗氧化活性为其作为抗感染抗氧化双功能肽药物的开发奠定了良好的基础。
5.Pb-CATH2的溶血活性分析
抽取5ml健康人静脉血,加入到装有5ml阿氏液(Alsever Solution:柠檬酸钠8g,柠檬酸0.55g,glucose 20.5g,NaCl 4.2g,加1L双蒸水,调PH至6.1,高压灭菌后4℃保存备用)的离心管中,1000rpm离心5min。用生理盐水(0.9%NaCl)洗涤至上清液不再呈红色为止。
将洗涤好的红细胞加生理盐水稀释成107-108cells/ml浓度的细胞悬液(约将200μl的细胞细胞沉淀加入到10ml的生理盐水中),然后将稀释好的红细胞悬浮液与溶解于生理盐水中的不同浓度的样品(PCR管中,加入90μl稀释好的细胞悬液及10μl不同浓度的样品)在37℃保温30min,然后1000rpm离心5min,取50μl的上清液于96孔板中,在540nm处测吸光值。同时该实验以1%Triton X-100作阳性对照,以生理盐水作阴性对照。每组做3个平行试验,溶血率=(样品540nm光吸收值-阴性对照)×100%/(阳性对照-阴性对照)。
实验结果表明,在浓度高达200μg/ml(59μM)时,Pb-CATH2对人红细胞溶血百分比仅为7.34%,在其杀菌MIC剂量范围内的12.5μg/ml(3.69μM),25μg/ml(7.39μM),50μg/ml(14.77μM)及100μg/ml(29.55μM)时,Pb-CATH2的人红细胞溶血百分比分别为4.76%,5.52%,7.07%及7.28%。这些都表明Pb-CATH2基本上不具有溶血活性,低溶血活性也为其药物研发奠定了基础。
Claims (4)
1.一种抗感染抗氧化双功能肽Pb-CATH2,其特征在于,cathelicidin家族双功能多肽Pb-CATH2是直链多肽,含有29个氨基酸残基,理论等电点为12.49,分子量是3389.08Da,其序列为:赖氨酸-精氨酸-天冬酰胺-甘氨酸-苯丙氨酸-精氨酸-赖氨酸-苯丙氨酸-甲硫氨酸-精氨酸-精氨酸-亮氨酸-赖氨酸-赖氨酸-苯丙氨酸-苯丙氨酸-丙氨酸-甘氨酸-甘氨酸-甘氨酸-丝氨酸-丝氨酸-异亮氨酸-丙氨酸-组氨酸-异亮氨酸-赖氨酸-亮氨酸-组氨酸。
2.按权利要求1所述抗感染抗氧化双功能肽Pb-CATH2的编码基因,其特征在于,核苷酸序列为:
aagcggaatg gttttcgcaa gttcatgaga
agactgaaga aattttttgc cggaggggga tcatccattg cacatataaa acttcattga。
3.权利要求1所述抗感染抗氧化双功能肽Pb-CATH2的应用,其特征在于,用于药理活性检测,或用于制备抗感染抗氧化药物,或用于化妆品、保健品、食品、饲料的添加剂。
4.权利要求2所述抗感染抗氧化双功能肽Pb-CATH2的编码基因的应用,其特征在于,根据编码基因重组表达Pb-CATH2。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510560842.7A CN105085647B (zh) | 2015-09-07 | 2015-09-07 | 天然抗感染抗氧化双功能肽Pb-CATH2及其基因与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510560842.7A CN105085647B (zh) | 2015-09-07 | 2015-09-07 | 天然抗感染抗氧化双功能肽Pb-CATH2及其基因与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105085647A CN105085647A (zh) | 2015-11-25 |
CN105085647B true CN105085647B (zh) | 2018-06-08 |
Family
ID=54567046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510560842.7A Active CN105085647B (zh) | 2015-09-07 | 2015-09-07 | 天然抗感染抗氧化双功能肽Pb-CATH2及其基因与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105085647B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110386972B (zh) * | 2019-08-23 | 2021-08-13 | 中国药科大学 | 抗菌多肽Pb2-1或PCL-1及其制备方法和应用 |
CN110590927B (zh) * | 2019-09-17 | 2022-06-14 | 济宁医学院 | 多疣壁虎抗氧化肽及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101845092A (zh) * | 2010-04-29 | 2010-09-29 | 大连理工大学 | 家畜驴的一种抗微生物肽Ea-CATH1及其基因和应用 |
WO2011109469A1 (en) * | 2010-03-03 | 2011-09-09 | Neocutis Sa | Compositions and methods for treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9325698D0 (en) * | 1993-12-15 | 1994-02-16 | Richardson James B | Patient-operated orthopedic device |
-
2015
- 2015-09-07 CN CN201510560842.7A patent/CN105085647B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011109469A1 (en) * | 2010-03-03 | 2011-09-09 | Neocutis Sa | Compositions and methods for treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds |
CN101845092A (zh) * | 2010-04-29 | 2010-09-29 | 大连理工大学 | 家畜驴的一种抗微生物肽Ea-CATH1及其基因和应用 |
Non-Patent Citations (2)
Title |
---|
Identification and characterization of novel reptile cathelicidins from elapid snakes;HuiZhao 等;《Peptides》;20080624;第29卷;第1687页左栏第4段、第1688页右栏第1段、第1689页左栏第1段、第1690页右栏第2段、图1-2 * |
PREDICTED: Python bivittatus cathelicidin-OH antimicrobial peptide-like(LOC103052957),mRNA;NCBI;《GenBank Database》;20140401;ccession No.XM_007443208.1 * |
Also Published As
Publication number | Publication date |
---|---|
CN105085647A (zh) | 2015-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103932914B (zh) | 壳聚糖漱口液及其制备方法 | |
CN104761629B (zh) | 一种广谱高效抗微生物肽Pb‑CATH‑OH1及其基因、制备方法和应用 | |
CN104292298A (zh) | 多肽、编码该多肽的dna分子、载体、制备方法及应用 | |
WO2006010147A2 (en) | Control of biofilm formation | |
CN105085647B (zh) | 天然抗感染抗氧化双功能肽Pb-CATH2及其基因与应用 | |
CN106188264A (zh) | 一种抗微生物肽Cm‑CATH3及其基因、制备方法和应用 | |
CN102363040B (zh) | 用于粘膜组织的抗微生物肽制剂 | |
CN105254736B (zh) | 源于缅甸蟒的cathelicidin家族广谱抗微生物肽Pb-CATH4及其基因、制备与应用 | |
JPWO2010004653A1 (ja) | ヘリコバクターピロリ菌の駆除剤並びに駆除方法 | |
CN102816223B (zh) | 细鳞鱼Cathelicidin抗微生物肽CATH_BRALE及其基因、制备、应用 | |
CN113527461B (zh) | 一种马铁菊头蝠来源抗菌肽rf-cath1及其应用 | |
CN103936845B (zh) | 一种源于中华鳖的抗微生物肽及其基因、制备方法和应用 | |
CN106361688B (zh) | 鼻腔洗液及其制备方法和应用 | |
CN104910265B (zh) | 一种合江棘蛙抗菌肽及其编码序列的基因与应用 | |
CN104083406B (zh) | 一种复方消毒液及其制备方法 | |
TWI309238B (en) | Protein and nucleic acid for glutathione-dependent formaldehyde dehydrogenase (gfd), alcohol dehydrogenase and s-nitrosoglutathione reductase from antrodia camphorata, manufacturing method and uses therefor | |
CN106727471A (zh) | 肌醇作为氟苯尼考增效剂的应用 | |
CN102796176B (zh) | 一种昆嵛林蛙抗菌肽Kunyuenin及其制备和应用 | |
CN102754666A (zh) | 医疗机构物体表面草本消毒剂 | |
CN102115496A (zh) | 一种抗微生物肽Pc-CATH1及其基因、化学合成方法和应用 | |
RU2622745C2 (ru) | Композиции на основе биоресурсов для профилактики или лечения сепсиса и/или связанных с сепсисом осложнений и состояний, способы профилактики и лечения сепсиса | |
CN110028557A (zh) | 一种Ce6标记的双链抗菌肽及其合成方法和应用 | |
Manzoor et al. | Comparative anticoccidial activity of hydrochloric acid (HCl) and formic acid against Eimeria tenella in broiler chickens | |
CN109627314A (zh) | 具有选择性抗大肠杆菌活性的抗菌肽及其活性优化修饰物 | |
CN105859859B (zh) | 一种用于防治疾病的饲料添加剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |